Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis

被引:70
作者
Sogabe, H
Nangaku, M
Ishibashi, Y
Wada, T
Fujita, T
Sun, XJ
Miwa, T
Madaio, MP
Song, WC
机构
[1] Univ Penn, Sch Med, Dept Pharmacol, Ctr Expt Therapeut, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA
关键词
D O I
10.4049/jimmunol.167.5.2791
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To prevent complement-mediated autologous tissue damage, host cells express a number of membrane-bound complement inhibitors. Decay-accelerating factor (DAF, CD55) is a GPI-linked membrane complement regulator that is widely expressed in mammalian tissues including the kidney. DAF inhibits the C3 convertase of both the classical and alternative pathways. Although DAF deficiency contributes to the human hematological syndrome paroxysmal nocturnal hemoglobinuria, the relevance of DAF in autoimmune tissue damage such as immune glomerulonephritis remains to be determined. In this study, we have investigated the susceptibility of knockout mice that are deficient in GPI-anchored DAF to nephrotoxic serum nephritis. Injection of a sub-nephritogenic dose of rabbit anti-mouse glomerular basement membrane serum induced glomerular disease in DAF knockout mice but not in wild-type controls. When examined at 8 days after anti-glomerular basement membrane treatment, DAF knockout mice had a much higher percentage of diseased glomeruli than wild-type mice (68.8 +/- 25.0 vs 10.0 +/- 3.5%; p < 0.01). Morphologically, DAF knockout mice displayed increased glomerular volume (516 +/- 68 vs 325 +/- 18 X 10(3) mum(3) per glomerulus; p < 0.0001) and cellularity (47.1 +/- 8.9 vs 32.0 +/- 3.1 cells per glomerulus; p < 0.01). Although the blood urea nitrogen level showed no difference between the two groups, proteinuria was observed in the knockout mice but not in the wild-type mice (1.4 +/- 0.7 vs 0.02 +/- 0.01 mg/24 h albumin excretion). The morphological and functional abnormalities in the knockout mouse kidney were associated with evidence of increased complement activation in the glomeruli. These results support the conclusion that membrane C3 convertase inhibitors like DAF play a protective role in complement-mediated immune glomerular damage in vivo.
引用
收藏
页码:2791 / 2797
页数:7
相关论文
共 56 条
[1]   Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney [J].
Abe, K ;
Miyazaki, M ;
Koji, T ;
Furusu, A ;
Ozono, Y ;
Harada, T ;
Sakai, H ;
Nakane, PK ;
Kohno, S .
KIDNEY INTERNATIONAL, 1998, 54 (01) :120-130
[2]  
[Anonymous], 1998, HUMAN COMPLEMENT SYS
[3]  
Beurskens FJM, 1999, CLIN EXP IMMUNOL, V116, P395
[4]  
BOYCE NW, 1985, J IMMUNOL, V135, P3918
[5]   Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis [J].
Clynes, R ;
Dumitru, C ;
Ravetch, JV .
SCIENCE, 1998, 279 (5353) :1052-1054
[6]   Molecular mechanisms of experimental glomerulonephritis: An overview [J].
Couser, WG ;
Nangaku, M ;
Shankland, SJ ;
Johnson, RJ .
NEPHROLOGY, 1997, 3 :S633-S637
[7]   CD59, AN LY-6-LIKE PROTEIN EXPRESSED IN HUMAN LYMPHOID-CELLS, REGULATES THE ACTION OF THE COMPLEMENT MEMBRANE ATTACK COMPLEX ON HOMOLOGOUS CELLS [J].
DAVIES, A ;
SIMMONS, DL ;
HALE, G ;
HARRISON, RA ;
TIGHE, H ;
LACHMANN, PJ ;
WALDMANN, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (03) :637-654
[8]   Different mediator systems in biphasic heterologous phase of anti-GBM nephritis in mice [J].
Feith, GW ;
Assmann, KJM ;
Bogman, MJJT ;
vanGompel, APM ;
Schalkwijk, J ;
Koene, RAP .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (04) :599-607
[9]   Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: A podocyte disease [J].
Floege, J ;
Hackmann, B ;
Kliem, V ;
Kriz, W ;
Alpers, CE ;
Johnson, RJ ;
Kuhn, KW ;
Koch, KM ;
Brunkhorst, R .
KIDNEY INTERNATIONAL, 1997, 51 (01) :230-243
[10]   Molecular cloning of murine decay accelerating factor by immunoscreening [J].
Fukuoka, Y ;
Yasui, A ;
Okada, N ;
Okada, H .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (03) :379-385